Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Bavencio 200mg/10ml concentrate for inf vials
0801050CFBBAAAA
|
Bavencio | Avelumab | Malignant Disease and Immunosuppression | No data available |
|
Belatacept 250mg powder for solution for infusion vials
0802020Y0AAAAAA
|
Belatacept | Belatacept | Malignant Disease and Immunosuppression | No data available |
|
Belumosudil 200mg tablets
0802040BEAAAAAA
|
Belumosudil | Belumosudil | Malignant Disease and Immunosuppression | No data available |
|
Besponsa 1mg pdr for concentrate for inf
0801050CEBBAAAA
|
Besponsa | Inotuzumab | Malignant Disease and Immunosuppression | No data available |
|
Besremi 250micrograms/0.5ml inj pre-filled pens
0802040BCBBAAAA
|
Besremi | Ropeginterferon alfa | Malignant Disease and Immunosuppression | No data available |
|
Betaferon 300microgram inj vials
0802040M0BCAAAD
|
Betaferon | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 1.25mg/0.05ml solution for injection vials
0801050APAAACAC
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 100mg/4ml solution for infusion vials
0801050APAAAAAA
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 400mg/16ml solution for infusion vials
0801050APAAABAB
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevqolva 100mg/4ml concentrate for inf vials
0801050APBJAAAA
|
Bevqolva | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevqolva 400mg/16ml concentrate for inf vials
0801050APBJABAB
|
Bevqolva | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bicalutamide 150mg/5ml oral suspension
0803042A0AAADAD
|
Bicalutamide | Bicalutamide | Malignant Disease and Immunosuppression | No data available |
|
Bicalutamide 50mg/5ml oral suspension
0803042A0AAACAC
|
Bicalutamide | Bicalutamide | Malignant Disease and Immunosuppression | No data available |
|
BiCNU 100mg inf vials
0801010D0BBAAAA
|
BiCNU | Carmustine | Malignant Disease and Immunosuppression | No data available |
|
Binimetinib 15mg tablets
0801050CNAAAAAA
|
Binimetinib | Binimetinib | Malignant Disease and Immunosuppression | No data available |
|
Binimetinib 45mg tablets
0801050CNAAABAB
|
Binimetinib | Binimetinib | Malignant Disease and Immunosuppression | No data available |
|
Bleo-Kyowa 15,000unit inj vials
0801020G0BCAAAA
|
Bleo-Kyowa | Bleomycin | Malignant Disease and Immunosuppression | No data available |
|
Bleomycin 15,000unit powder for solution for injection vials
0801020G0AAAAAA
|
Bleomycin | Bleomycin | Malignant Disease and Immunosuppression | No data available |
|
Bortezomib 3.5mg powder for solution for injection vials
0801050ACAAAAAA
|
Bortezomib | Bortezomib | Malignant Disease and Immunosuppression | No data available |
|
Bosulif 100mg tablets
0801050BLBBAAAA
|
Bosulif | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosulif 400mg tablets
0801050BLBBACAC
|
Bosulif | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosulif 500mg tablets
0801050BLBBABAB
|
Bosulif | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosutinib 100mg tablets
0801050BLAAAAAA
|
Bosutinib | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosutinib 400mg tablets
0801050BLAAACAC
|
Bosutinib | Bosutinib | Malignant Disease and Immunosuppression | No data available |
|
Bosutinib 500mg tablets
0801050BLAAABAB
|
Bosutinib | Bosutinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.